Shearman & Sterling advised Ibere Pharmaceuticals, a blank check company formed for the purpose of effecting a merger in the pharmaceutical and life sciences industries, in its $138 million initial public offering. Ibere Pharmaceuticals is listed on the New York Stock Exchange and commenced trading on February 26, 2021 under the ticker symbol "IBERU."
The Team
Industries
Regional Experience